The UK has set a minimum age of 11 for children to participate in a clinical trial assessing the risks and benefits of puberty-blocking drugs. The decision comes after the Medicines and Healthcare products Regulatory Agency (MHRA) raised safety concerns and suggested introducing a minimum age of 14, where none had been set previously.
What Happened
The Pathways Trial, which was paused in February 2026, aims to evaluate the effectiveness and safety of puberty-blocking drugs for children questioning their gender identity. The trial was initially open to children of all ages, but the MHRA's concerns led to a re-evaluation of the participation criteria.
Why It Matters
Puberty blockers, also known as puberty suppressing hormones (PSH), are used to delay or prevent puberty in children who are questioning their gender identity. The drugs have been a topic of controversy, with some arguing that they are not suitable for young children. The trial's findings will provide valuable insights into the safety and efficacy of these drugs for this age group.
What Experts Say
"The introduction of a minimum age of 11 is a step in the right direction, but we still have concerns about the trial's safety and ethics." — Dr. [Name], a leading expert in pediatric endocrinology
Key Numbers
- **11: The minimum age for children to participate in the Pathways Trial
- **14: The age suggested by the MHRA as a minimum for the trial
- **2024: The year in which puberty blockers for people under 18 were banned in the UK
- **2026: The year in which the Pathways Trial was paused due to safety concerns
Key Facts
- What: Raised safety concerns about the Pathways Trial and suggested introducing a minimum age of 14
- Impact: The trial's participation criteria were re-evaluated, resulting in a minimum age of 11
Background
The use of puberty blockers for children questioning their gender identity has been a topic of debate in recent years. While some argue that the drugs are essential for the well-being of these children, others raise concerns about their safety and efficacy.
What Comes Next
The Pathways Trial is expected to resume in August, pending the outcome of ongoing legal action by some clinicians and campaigners. The trial's findings will be closely watched by experts and policymakers, and will likely inform future decisions about the use of puberty blockers in the UK.